• AI-Driven Senolytic Discovery: Machine Learning Unveils New

  2026-06-19

  The reference study uses machine learning to identify novel senolytic compounds, validating their efficacy across diverse senescence models and demonstrating significant reductions in drug discovery costs. These findings highlight the potential of AI-based chemical screening for accelerating therapeutic innovation in cancer biology, aging, and related fields.

• Phillygenin Attenuates Diabetic Nephropathy via Inflammation

  2026-06-19

  This study establishes phillygenin as a novel modulator of diabetic nephropathy, demonstrating that it suppresses inflammation and apoptosis in kidney cells by targeting TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. These findings highlight molecular mechanisms underlying phillygenin’s renal protective effects and provide a foundation for future translational research in diabetic kidney disease.

• Norovirus Utilizes NINJ1 for Selective NS1 Protein Secretion

  2026-06-18

  Song et al. reveal that murine norovirus exploits the host membrane protein NINJ1 to selectively secrete its NS1 viral protein through a caspase-3–dependent, unconventional pathway. This discovery advances understanding of virus–host interplay in regulated protein secretion and programmed cell death, offering new insights for apoptosis-related research across domains.

• KG-501: Applied CREB–KIX Disruption for Oncology Research

  2026-06-18

  KG-501, a potent CREB-mediated transcription inhibitor, empowers translational and preclinical researchers to dissect oncogenic signaling and immune modulation mechanisms with exceptional precision. This article delivers actionable workflows, troubleshooting insights, and data-driven enhancements for leveraging KG-501 as a transcriptional coactivator disruptor in cancer and immunology models.

• Myriocin in Sphingolipid Metabolism: Systems Biology Insight

  2026-06-17

  Explore how Myriocin, a potent serine palmitoyltransferase inhibitor, enables advanced sphingolipid metabolism research and systems-level understanding of cell fate. This article uniquely bridges molecular inhibition with network pharmacology, offering new assay perspectives.

• FLT3-TAZ Signaling Drives Drug Resistance in Blast Phase CML

  2026-06-17

  Shin et al. demonstrate that FLT3 activation underpins drug resistance in blast phase chronic myeloid leukemia (BP-CML), independent of BCR::ABL1 mutations. Their work introduces FLT3 as a prognostic marker and actionable therapeutic target, expanding FLT3 inhibition strategies beyond acute myeloid leukemia (AML) models.

• PR-619: Practical Guidelines for Broad-Spectrum DUB Inhibiti

  2026-06-16

  PR-619 is a reversible, cell-permeable inhibitor for broad cysteine-dependent deubiquitylating enzymes (DUBs), enabling accumulation of ubiquitinated proteins in cell-based assays without direct proteasome inhibition. Its optimal use is in workflows studying the ubiquitination pathway, autophagy, or protein aggregation in cancer and neurodegenerative disease models, but it is not recommended when aqueous solubility or long-term solution storage is required.

• Diethylmaleate for Redox Regulation and Resistance Research

  2026-06-16

  Diethylmaleate enables targeted glutathione depletion and GST inhibition, unlocking precise oxidative stress modeling and resistance mechanism studies. This guide distills experimental workflows and troubleshooting strategies to maximize its impact in toxicology and redox biology research.

• Rapamycin (Sirolimus): Advanced Workflows in Immunology and

  2026-06-15

  Rapamycin (Sirolimus) enables precise mTOR pathway interrogation, streamlining immune cell modulation and disease modeling. Learn how to optimize protocols for apoptosis induction, T cell suppression, and mitochondrial research—plus actionable troubleshooting strategies for reproducible results.

• SC 79 Akt Activator: Optimizing Neuroprotection Assays

  2026-06-15

  SC 79 stands out as a versatile Akt activator enabling cytosolic Akt phosphorylation for neuroprotection and cell survival studies. This guide delivers actionable protocol parameters, troubleshooting tactics, and evidence-backed insights, empowering researchers to maximize reliability in ischemic stroke and Akt signaling assays.

• Masitinib (AB1010): Technical Guide for KIT/PDGFR Research

  2026-06-14

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor for targeted inhibition of KIT and PDGFR signaling in cancer, mastocytosis, and inflammatory disease research. It is best suited for DMSO-based workflows where precise inhibition of specific kinases is required, but should not be used in studies demanding broad-spectrum kinase activity or aqueous/ethanol compatibility.

• SB 203580: Dual-Action Insights for p38 MAPK Research

  2026-06-13

  Explore the dual-action mechanism of SB 203580 in p38 MAPK signaling pathway research. This in-depth article reveals new structural and functional insights, advancing beyond protocol guides to inform assay design and translational applications.

• Technical Guide: HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-06-12

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus addresses the challenge of generating high-yield, fluorescently labeled RNA probes for sensitive detection assays such as in situ hybridization and Northern blotting. This kit is strictly for research workflows and is not validated for diagnostic, therapeutic, or clinical use.

• EPZ5676: Advancing DOT1L Inhibition for Epigenetic Leukemia

  2026-06-12

  Explore how EPZ5676, a potent DOT1L inhibitor, transforms epigenetic research in MLL-rearranged leukemia with unprecedented selectivity and in vivo efficacy. This article delivers practical assay insights and a deeper mechanistic perspective not covered elsewhere.

• Boosting mRNA Loading in Kidney-Targeted Nanoparticles: Exci

  2026-06-11

  This study systematically investigates how incorporating various excipients can enhance the mRNA loading capacity of polymeric mesoscale nanoparticles designed for kidney-targeted delivery. By testing agents such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), trehalose, and calcium acetate, the research addresses technical limitations in mRNA encapsulation, with direct implications for improving nanoparticle-based renal therapeutics.

15938 records 1/1063 page Next 12345 下5页 Last page